Hambartsoumian E
Service de Gynécologie/Obstétrique, Hôpital Antoine Béclère, Clamart, France.
Am J Reprod Immunol. 1998 Feb;39(2):137-43. doi: 10.1111/j.1600-0897.1998.tb00345.x.
The possible role of leukemia inhibiting factor (LIF) in unexplained infertility and multiple failures of implantation (MFI) was evaluated.
By a specific and sensitive enzyme-linked immunosorbent assay (ELISA), the in vitro endometrial LIF secretion by explant cultures from women with unexplained infertility (n = 32) was examined. Endometrial samples were obtained on either days 8-11 of the proliferative phase or days 18-21 of the secretory phase. In some subjects (n = 11) an endometrial biopsy was performed twice, both in the proliferative and in the secretory phase of the cycle. The control group consisted of fertile women (n = 17).
In fertile women the endometrial LIF secretion was 2.2 times higher in the secretory phase samples than in the proliferative phase samples (mean +/- SEM, 3259 +/- 314 pg in the proliferative phase vs. 7726 +/- 1192 in the secretory phase; P < 0.05). In contrast, infertile women exhibited no such elevation of cytokine production. Moreover, in infertile women with MFI the level of LIF in the secretory phase demonstrated the tendency to decrease (mean +/- SEM, 4953 +/- 1125 pg vs. 2162 +/- 541 pg; P > 0.05). When the amount of cytokine secretion was compared on the same day of the cycle between the two groups of women, the LIF production in fertile women on days 18-21 of the menstrual cycle was 3.5 times greater than in the infertile women with MFI and 2.2 times greater than in women without MFI (P < 0.01 and P < 0.05, respectively). On days 8-11 of the cycle, the level of LIF in these groups did not differ significantly, however, in infertile women the range of distribution of cytokine was largely varied, demonstrating the highest amplitude of variations in subjects with MFI. Analyses of the data for women to whom LIF was examined in both phases of the cycle showed that some subjects (27%) exhibited an elevated amount of LIF in the secretory phase of the cycle. This suggests that in these cases the endometrial factor(s) may be irrelevant to infertility.
In the majority of infertile women there is a deregulation of LIF production in the endometrium during both the proliferative and the secretory phases of the cycle. The dysfunction of cytokine production is more profound in patients with MFI. The deregulation of endometrial LIF secretion throughout the menstrual cycle may be a possible cause of unexplained infertility and repetitive failures of implantation.
评估白血病抑制因子(LIF)在不明原因不孕症和反复种植失败(MFI)中可能发挥的作用。
采用特异性和敏感性均较高的酶联免疫吸附测定(ELISA)法,检测不明原因不孕症患者(n = 32)外植体培养物的体外子宫内膜LIF分泌情况。在增殖期的第8 - 11天或分泌期的第18 - 21天获取子宫内膜样本。部分受试者(n = 11)在月经周期的增殖期和分泌期均进行了子宫内膜活检。对照组为有生育能力的女性(n = 17)。
有生育能力的女性,分泌期样本的子宫内膜LIF分泌量比增殖期样本高2.2倍(均值±标准误,增殖期为3259±314 pg,分泌期为7726±1192 pg;P < 0.05)。相比之下,不孕女性未出现这种细胞因子分泌量的升高。此外,患有MFI的不孕女性,其分泌期的LIF水平呈下降趋势(均值±标准误,分别为4953±1125 pg和2162±541 pg;P > 0.05)。当比较两组女性在月经周期同一天的细胞因子分泌量时,月经周期第18 - 21天有生育能力女性的LIF分泌量比患有MFI的不孕女性高3.5倍,比未患MFI的不孕女性高2.2倍(P分别< 0.01和P < 0.05)。在月经周期的第8 - 11天,这些组的LIF水平无显著差异,然而,在不孕女性中,细胞因子的分布范围差异很大,MFI患者的变化幅度最大。对在月经周期两个阶段均检测了LIF的女性数据进行分析表明,部分受试者(27%)在月经周期的分泌期LIF分泌量升高。这表明在这些情况下,子宫内膜因素可能与不孕无关。
在大多数不孕女性中,月经周期的增殖期和分泌期子宫内膜LIF的产生均失调。细胞因子产生功能障碍在患有MFI的患者中更为严重。整个月经周期子宫内膜LIF分泌失调可能是不明原因不孕症和反复种植失败的一个可能原因。